The price you pay for Epidiolex may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

GW Pharmaceuticals is closing in on a US filing for its cannabinoid epilepsy drug, Epidiolex, after trumpeting late-stage study findings. The company specialises in drugs derived from the cannabis ...

UK-based GW Pharmaceuticals’ Epidiolex looks on course for approval in the US, after a panel of FDA experts unanimously backed it as a treatment for two rare forms of epilepsy. The FDA's ...

Professor O’Sullivan’s presentation, “A Cannabidiol Cocrystal (ART12.11) Tablet Has Comparable Pharmacokinetics to Epidiolex,” highlighted results from canine studies evaluating Artelo’s ...

GW contributed $991 million to Jazz's overall 2024 revenue, largely driven by its leading product, Epidiolex. This drug is a cannabidiol for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals JAZZ reported fourth-quarter 2024 adjusted earnings of $6.60 per share, which beat the Zacks Consensus Estimate of $5.79. Earnings rose 31% year over year. Total revenues rose 8% ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced it is buying Chimerix (Nasdaq: CMRX) for $8.55 per share in cash, ...

Morningstar brands and products Company Portfolio ...

Jazz Pharmaceuticals PLC (JAZZ) achieves record-breaking revenue in 2024, outlines strategic growth initiatives for 2025 amidst competitive challenges.

Total revenues rose 8% year over year to $1.09 billion. Sales of Xywav and Epidiolex drove this upside. The reported figure beat the Zacks Consensus Estimate of $1.06 billion. See the Zacks ...